Year: 2019
Type: review
Abstract: Cancer therapy has entered a new era, transitioning from unspecific chemotherapeutic agents to increasingly specific immune-based therapeutic strategies. Among these, chimeric antigen receptor (CAR) T cells have shown unparalleled therapeutic potential in treating refractory hematological malignancies. In contrast, solid tumors pose a much greater challenge to CAR T cell therapy, which has yet to be overcome. As this novel therapeutic modality matures, increasing effort is being invested to determine the optimal structure and properties of CARs to facilitate the transition from empirical testing to the rational design of CAR T cells. In this review, we highlight how individual CAR domains contribute to the success and failure of this promising treatment modality and provide an insight into the most notable advances in the field of CAR T cell engineering.
Source: Cells
DOI: 10.3390/cells8050472
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $1,824
Funders: Melanoma Research Alliance, European Commission, Bundesministerium für Bildung und Forschung, Else Kröner-Fresenius-Stiftung, Jung-Stiftung für Wissenschaft und Forschung, Ludwig-Maximilians-Universität München, Deutsche Krebshilfe, Horizon 2020 Framework Programme, European Research Council, Elitenetzwerk Bayern, H2020 European Research Council
OpenAlex ID: W2946717294
